BioWorld

May 24, 2006

Pharmacopeia Rises On Deal With Cephalon: $15M Up Front

Shares of Pharmacopeia Drug Discovery Inc. jumped 26.3 percent after the company signed a drug discovery deal with Cephalon Inc. that includes a $15 million up-front fee and the potential for double-digit royalties. (BioWorld Today) Read More

Avanir Buys Alamo, Gains CNS Product, Sales Force

New River Starts Phase III Study For NRP104 Against Adult ADHD

BioWorld Releases First Report On Top 25 Biotechnology Drugs

Hold On Avastin Study Lifted After 60-Day Review By DSMB

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...